Verve Therapeutics, Inc.

2022 Annual Meeting

Verve Therapeutics was created with a singular focus: to protect the world from cardiovascular disease.

We are striving to build the preeminent company developing gene editing medicines to treat patients with cardiovascular disease, leveraging the expertise and capabilities of our team whose singular focus is on addressing the root causes of the world’s most common cause of death. Our goal is to disrupt today’s chronic care model for treating cardiovascular disease by providing a new therapeutic approach with single-course gene editing treatments.

Verve brings together multiple breakthroughs in 21st century biomedicine — human genetic analysis, gene editing, messenger RNA (mRNA) -based therapies and lipid nanoparticle (LNP) delivery — to realize a new future of longevity and vitality for tens of millions of people around the globe with or at risk for cardiovascular disease.

Learn More →